Vaxart的Q4调查结果显示,尽管口服疫苗试验取得了进展,但收入仍然较低,没有给出批准时间表。 Vaxart's Q4 results showed lower revenue despite progress on oral vaccine trials, with no approval timelines given.

Vaxart报告说,尽管口服甲板疫苗开发工作有所进展,但其Q4收入呼唤的结果好坏参半,收入低于预期。 Vaxart reported mixed results in its Q4 earnings call, with revenue falling short of expectations despite progress in its oral tablet vaccine development. 该公司强调正在进行的临床试验和潜在的伙伴关系,但没有提供批准产品的具体时间表。 The company emphasized ongoing clinical trials and potential partnerships but did not provide specific timelines for product approval. Vuzix和Zumiez也发布了Q4最新消息,Vuzix强调智能眼镜销售的增长,Zumiez指出同一商店的销售有所改善,尽管两者都警告说影响消费者支出的宏观经济压力。 Vuzix and Zumiez also released Q4 updates, with Vuzix highlighting growth in smart glasses sales and Zumiez noting improved same-store sales, though both cautioned about macroeconomic pressures affecting consumer spending.